{"organizations": [], "uuid": "7c44d4151e96ed7fa72c8e15ce2cbefd9b8894ce", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000551/device/rss", "section_title": "California", "url": "https://www.cnbc.com/2018/03/15/the-associated-press-asterias-biotherapeutics-posts-4q-loss.html", "country": "US", "domain_rank": 767, "title": "Asterias Biotherapeutics posts 4Q loss", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-16T00:07:00.000+02:00", "replies_count": 0, "uuid": "7c44d4151e96ed7fa72c8e15ce2cbefd9b8894ce"}, "author": "cnbc.com", "url": "https://www.cnbc.com/2018/03/15/the-associated-press-asterias-biotherapeutics-posts-4q-loss.html", "ord_in_thread": 0, "title": "Asterias Biotherapeutics posts 4Q loss", "locations": [], "entities": {"persons": [], "locations": [{"name": "fremont", "sentiment": "none"}, {"name": "calif.", "sentiment": "none"}], "organizations": [{"name": "ast", "sentiment": "negative"}, {"name": "asterias biotherapeutics inc.", "sentiment": "negative"}, {"name": "asterias biotherapeutics", "sentiment": "negative"}, {"name": "ap", "sentiment": "negative"}, {"name": "zacks investment research", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "FREMONT, Calif. (AP) _ Asterias Biotherapeutics Inc. (AST) on Thursday reported a loss of $6.5 million in its fourth quarter.\nOn a per-share basis, the Fremont, California-based company said it had a loss of 12 cents.\nThe results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 15 cents per share.\nThe stem cell therapy developer posted revenue of $28,000 in the period.\nFor the year, the company reported that its loss narrowed to $28.4 million, or 56 cents per share. Revenue was reported as $4 million.\nIn the final minutes of trading on Thursday, the company's shares hit $1.95. A year ago, they were trading at $3.20.\nThis story was generated by Automated Insights ( http://automatedinsights.com/ap ) using data from Zacks Investment Research. Access a Zacks stock report on AST at https://www.zacks.com/ap/AST", "external_links": [], "published": "2018-03-16T00:07:00.000+02:00", "crawled": "2018-03-16T01:08:00.010+02:00", "highlightTitle": ""}